Transfusion Medicine Reviews
Volume 24, Issue 2 , Pages 77-124 , April 2010

Blood Still Kills: Six Strategies to Further Reduce Allogeneic Blood Transfusion-Related Mortality

  • Eleftherios C. Vamvakas

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Eleftherios C. Vamvakas, MD, PhD, Room 3733, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.
    • ,
  • Morris A. Blajchman

References 

  1. FDA/CBER: Fatalities reported to the FDA following blood collection and transfusion . Annual summary for fiscal year 2008. Available at http://www.fda.gov/cber/blood/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM113649.htmAccessed September 21, 2009
  2. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25:573–577
  3. Goldman M, Blajchman MA. Blood products-associated bacterial sepsis. Transfus Med Rev. 1991;5:73–83
  4. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion. 1990;30:583–590
  5. Popovsky MA, Chaplin HC, Moore SB. Transfusion-related acute lung injury: A neglected, serious complication of hemotherapy. Transfusion. 1992;32:589–592
  6. Blajchman MA, Ali AM. Bacteria in the blood supply: An overlooked issue in transfusion medicine. In:  Nance SJ editors. Blood safety: Current challenges. Bethesda, MD: American Association of Blood Banks; 1992;p. 213–228
  7. Dodd RY, Shoos Lipton K. Further guidance on methods to detect bacterial contamination of platelet components. AABB Association Bulletin #03-12 (October 1, 2003). Available at http://www.aabb.org/Content/Members_Area/Association_Bulletins/ab03-12.htmAccessed September 21, 2009
  8. Strong DM, Shoos Lipton K. Transfusion-related acute lung injury. AABB Association Bulletin #06-07 (November 3, 2006). Available at http://www.aabb.org/Content/Members_Area/Association_Bulletins/ab0607.htmAccessed September 21, 2009
  9. McDonald CP, Blajchman MA. Bacterial contamination in blood and blood components. In:  Barbara JSJ,  Regan FAM,  Contreras MC editor. Transfusion microbiology. Cambridge, UK: Cambridge University Press; 2008;p. 87–115
  10. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: Definition and review. Crit Care Med. 2005;33:721–726
  11. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: Statement of a consensus panel. Transfusion. 2004;44:1774–1789
  12. Middleberg RA, van Stein D, Briet E, et al. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: A systematic review. Transfusion. 2008;48:2167–2176
  13. Trilzi DJ, Kleinman S, Kakaiya RM, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: Implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion. 2009;49:1825–1835
  14. Andreu G, Morel P, Forester F, et al. Hemovigilance network in France: Organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion. 2002;42:1356–1364
  15. Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: A decade of hemovigilance in the UK. Transfus Med Rev. 2006;20:237–282
  16. Serious hazards of transfusion (SHOT) Annual Reports. Available at http://www.shot-uk.org2009;Accessed September 21
  17. Robillard P, Nawej KI, Jochem K. The Quebec hemovigilance system: Description and results from the first two years. Transfus Apher Sci. 2004;31:111–122
  18. Honig CL, Bove JR. Transfusion-associated fatalities: Review of Bureau of Biologics reports, 1976-78. Transfusion. 1980;20:653–661
  19. Holness L, Knippen MA, Simmons L, et al. Fatalities caused by TRALI. Transfus Med Rev. 2004;18:184–188
  20. Holness L, Knippen M, Simmons L. Characteristics of donors implicated in fatal transfusion-related acute lung injury (TRALI) reactions. Available at http://www.accessdata.fda.gov/ScienceForums/forum06/K-34.htmLast updated on 2008-Aug-28; accessed September 21, 2009
  21. Holness L, Jones P, Knippen M, et al. 19-year review of fatalities due to contaminated blood and blood components. Available at http://www.accessdata.fda.gov/ScienceForums/forum06/K-35.htmLast updated on 2008-Aug-28; accessed September 21, 2009
  22. Peterman TA, Lui KJ, Lawrence DN, et al. Estimating the risks of transfusion-associated acquired immune deficiency syndrome and human immunodeficiency virus infection. Transfusion. 1987;27:371–374
  23. Alter HJ. Pathogen reduction: A precautionary-principle paradigm. Transfus Med Rev. 2008;22:97–102
  24. Seef LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung and Blood Institute Collaborative Study. Hepatology. 2001;33:455–463
  25. Vamvakas EC, Taswell HF. Long-term survival after blood transfusion. Transfusion. 1994;34:471–477
  26. Vamvakas EC, Blajchman MA. Transfusion-related mortality: The on-going risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113:3406–3417
  27. Dodd RY. Germs, gels, and genomes: A personal recollection of 30 years in blood-safety testing. In:  Stramer SL editors. Blood safety in the new millenium. Bethesda, MD: American Association of Blood Banks; 2001;p. 99–121
  28. Murphy W. Managing threats rather than risks in blood transfusion: Robust design for a complex system. Transfusion. 2006;46:2011–2013
  29. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion. 2009;49(Suppl. 2):1S–236S
  30. van de Watering LMG, Hermans J, Houbiers JGA, et al. Beneficial effect of leukocyte depletion of transfused blood on post-operative complications in patients undergoing cardiac surgery: A randomized clinical trial. Circulation. 1998;97:562–568
  31. Bilgin YM, van de Watering LMG, Eijsman L, et al. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac-valve surgery. Circulation. 2004;109:2755–2760
  32. Boshkov LK, Furnary A, Morris C, et al. Pre-storage leukoreduction of red cells in elective cardiac surgery: Results of a double-blind randomized controlled trial. Blood. 2004;104:112a
  33. Vamvakas EC, Blajchman MA. Transfusion-related immunodulation (TRIM): An update. Blood Rev. 2007;21:327–348
  34. Murphy GJ, Reeves BC, Rogers CA, et al. Increased mortality, postoperative morbidity, and cost after red-blood-cell transfusion in patients having cardiac surgery. Circulation. 2007;116:2544–2552
  35. Netzer G, Shah CV, Iwashyna TJ, et al. Association of RBC transfusion with mortality in patients with acute lung injury. Chest. 2007;132:1116–1123
  36. Koch CG, Li L, Duncan AI, et al. Transfusion in coronary-artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg. 2006;81:1650–1657
  37. Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red-blood-cell and blood-component transfusion in isolated coronary-artery bypass grafting. Crit Care Med. 2006;34:1608–1616
  38. Marik PE, Corwin HL. Efficacy of red-blood-cell transfusion in the critically ill: A systematic review of the literature. Crit Care Med. 2008;36:2667–2674
  39. Hébert PC, Wells G, Blajchman MA, et al. A multicenter randomized controlled trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409–417
  40. Strong DM, AuBuchon J, Whitaker B, et al. Biovigilance initiatives. ISBT Sci Ser. 2008;3:77–84
  41. Robillard P, Hyson C, McCombie N. TRALI, possible TRALI and respiratory complications of transfusion reported to the Canadian Transfusion-Transmitted Injuries Surveillance System. Transfusion. 2007;47(Suppl.):5A;(abstract)
  42. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: Epidemiology and a prospective analysis of etiologic factors. Blood. 2003;101:454–462
  43. Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically ill: Prospective nested case-control study. Am J Respir Crit Care Med. 2007;176:886–891
  44. Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol. 2007;136:788–799
  45. Kehler MR, Masumo T, Moore EE, et al. Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model. Blood. 2009;113:2079–2087
  46. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105:2266–2273
  47. Ness P, Braine N, King K, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion. 2001;41:857–861
  48. Ness PM, Campbell-Lee SA. Single-donor versus pooled random-donor platelet concentrates. Curr Opin Hematol. 2001;8:392–396
  49. FDA/CBER: Transfusion-related acute lung injury letter (dated October 19, 2001; by Zoon KC). Available at http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/UCM105850.htmAccessed September 21, 2009
  50. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial co-ordination. Am J Respir Crit Care Med. 1994;149:818–824
  51. Abraham E, Matthay MA, Dinarello CA, et al. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a re-evaluation. Crit Care Med. 2000;28:232–235
  52. Meade MO, Guyatt GH, Cook RJ, et al. Agreement between alternative classifications of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;163:490–493
  53. FDA/CBER . Bacterial Contamination of Platelets Workshop: September 1999, Bethesda, MD. 1999;
  54. Brecher ME, Hay SN. Bacterial contamination of blood components. Clin Microbiol Rev. 2005;18:195–204
  55. Silva MA, Gregory KR, Carr-Greer MA, et al. Summary of the AABB Interorganizational Task Force on Bacterial Contamination of Platelets: Fall 2004 impact survey. Transfusion. 2006;46:636–641
  56. Whitaker BI, Green J, King MR, et al. The 2007 Nationwide Blood Collection and Utilization Survey Report. Washington DC: Department of Health and Human Services; 2008;
  57. Wallis JP, Lubenko A, Wells AW, et al. Single-hospital experience of TRALI. Transfusion. 2003;43:1053–1059
  58. Gubernot DM, Lucey CT, Leek C, et al. Babesia infection through blood transfusions: Reports received by the US Food and Drug Administration, 1997-2007. Clin Infect Dis. 2009;48:25–30
  59. Roth VR, Kuehnert MJ, Haley NR, et al. Evaluation of a reporting system for bacterial contamination of blood components in the United States. Transfusion. 2001;41:1486–1492
  60. Zou S, Wu Y, Cable R, et al. A prospective study of multiple-donor-exposure blood recipients: Surveillance value and limitations for hemovigilance. Transfusion. 2010;50:128–138
  61. Tambyah PA, Koay ESC, Poon MLM, et al. Dengue hemorrhagic fever transmitted by blood transfusion. N Engl J Med. 2008;359:1526–1527
  62. Seed CR, Kiely P, Hyland CA, et al. The risk of dengue transmission by blood during a 2004 outbreak in Cairns, Australia. Transfusion. 2009;49:1482–1487
  63. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975–979
  64. Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion. 2005;45:254–264
  65. Zou S, Musavi F, Notari EPIV, et al. Changing age distribution of the blood donor population in the US. Transfusion. 2008;48:251–257
  66. Zou S, Notari EP, Fang CT, et al. Current value of serologic test for syphilis as a surrogate marker for blood-borne viral infections among blood donors in the United States. Transfusion. 2009;49:655–661
  67. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window-period reduction and residual risk. J Clin Virol. 2006;36(Suppl.):S523–S529
  68. Kleinman SH, Busch M. Hepatitis B virus: Amplified and back in the blood safety spotlight. Transfusion. 2001;41:1081–1085
  69. Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: A hidden menace?. Hematology. 2001;34:204–206
  70. Bowden RA, Slichter SJ, Sayers MH, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV)-seronegative blood products for the prevention of transfusion-associated CMV infection after bone marrow transplant. Blood. 1995;86:3598–3606
  71. Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003;101:4195–4200
  72. Pealer LN, Martin AA, Petersen LR, et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med. 2003;349:1236–1245
  73. Macedo de Oliveira A, Beecham BD, Montgomery SP, et al. West Nile Virus blood transfusion-related infection despite nucleic acid testing. Transfusion. 2004;44:1695–1699
  74. Biggerstaff BJ, Petersen LR. Estimated risk of transmission of West Nile Virus through blood transfusion in the US, 2002. Transfusion. 2003;43:1007–1017
  75. Dodd RY. Emerging infections, transfusion safety, and epidemiology. N Engl J Med. 2003;349:1205–1206
  76. Rios M. Climate change and vector-borne viral diseases potentially transmitted by transfusion. ISBT Sci Ser. 2009;4:87–94
  77. Rezza G, Nicoletti L, Angelini R, et al. Infection with Chickungunya virus in Italy: An outbreak in a temperate region. Lancet. 2007;370:1840–1846
  78. National CJD Surveillance Unit. Available at www.cjd.ed.ac.uk/figures.htmAccessed August 28, 2009
  79. Ghani AC, Donnelly CA, Fergusson NM, et al. Updated projections of future vCJD deaths in the UK. BMC Infect Dis. 2003;3:4
  80. Hilton DA, Ghanmi AC, Conyers L, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol. 2004;203:733–739
  81. Collinge J, Whitfield J, McIntosh E, et al. Kuru in the 21st century: An acquired prion disease with very long incubation periods. Lancet. 2006;367:2068–2074
  82. Saa P, Castilla J, Soto C. Pre-symptomatic detection of prions in blood. Science. 2006;313:92–94
  83. Zou S, Fang CT, Schoenberger LB. Transfusion transmission of prion diseases. Transfus Med Rev. 2008;22:58–69
  84. Mungai M, Tegtmeier G, Chamberland M, et al. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med. 2001;344:1973–1978
  85. Slinger R, Giulivi A, Bodie-Collins M, et al. Transfusion-transmitted malaria in Canada. CMAJ. 2001;164:377–379
  86. Bruce-Chwatt LJ. Transfusion-transmitted malaria revisited. Trop Dis Bull. 1982;79:827–840
  87. Turc JM. Malaria and blood transfusion. In:  Westphal RG,  Carlson KB,  Turc JM editor. Emerging global patterns in transfusion-transmitted infections. Arlington, VA: American Association of Blood Banks; 1990;p. 31–43
  88. International forum: Are current measures to prevent transfusion-associated protozoal infections sufficient?. Vox Sang. 2004;87:125–138
  89. Leiby DA, Gill GE. Transfusion-transmitted tick-borne infections: A cornucopia of threats. Transfus Med Rev. 2004;48:293–306
  90. Gerber MA, Shapiro ED, Krause PJ, et al. The risk of acquiring Lyme disease or babesiosis from a blood transfusion. J Infect Dis. 1994;170:231–234
  91. Cardo LJ. Leishmania: Risk to the blood supply. Transfusion. 2006;46:1641–1645
  92. Leiby DA, Rentas FJ, Nelson KE, et al. Evidence of Trypanosoma cruzi infection (Chagas' disease) among patients undergoing cardiac surgery. Circulation. 2000;102:2978–2982
  93. Leiby DA. Threats to blood safety posed by emerging protozoan pathogens. Vox Sang. 2004;87(Suppl. 2):120–122
  94. Strong DM, Shoos Lipton K. Information concerning implementation of a licensed test for antibodies to Trypansonoma cruzi. AABB Association Bulletin #06-08 (December 14, 2006). Available at http://www.aabb.org/Content/Members_Area/Association_Bulletins/ab06:08.htmAccessed September 28, 2009
  95. Young C, Losikoff P, Chawla A, et al. Transfusion-acquired Trypanosoma cruzi infection. Transfusion. 2007;47:540–544
  96. Parrish CR, Holmes EC, Morens DM, et al. Cross-species virus transmission and the emergence of new epidemic diseases. Microbiol Mol Biol Rev. 2008;72:457–470
  97. Petersen LR, Hayes EB. Westward ho?—The spread of West Nile Virus. N Engl J Med. 2004;351:2257–2259
  98. Dodd RY. Current risk of transfusion-transmitted infections. Curr Opin Hematol. 2007;14:671–676
  99. Dodd RY, Leiby DA. Emerging infectious threats to the blood supply. Am Rev Med. 2004;55:191–207
  100. Alter HJ, Stramer SL, Dodd RY. Emerging infectious diseases that threaten the blood supply. Semin Hematol. 2007;44:32–41
  101. Goodnough LT, Brecher ME, Kanter MH, et al. Transfusion medicine. First of two parts—Blood transfusion. N Engl J Med. 1999;340:438–447
  102. Vamvakas EC. Relative safety of pooled whole-blood-derived versus single-donor (apheresis) platelets in the United States: A systematic review of disparate risks. Transfusion. 2009;49:2743–2758
  103. Perez P, Sahmi LR, Follea G, et al. Determinants of transfusion-associated bacterial contamination: Results of the French BACTHEM case-control study. Transfusion. 2001;41:862–872
  104. Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion. 2001;41:1493–1499
  105. Brecher ME, Holland PV, Pineda AA, et al. Growth of bacteria in inoculated platelets: Implications for bacterial detection and the extension of platelet storage. Transfusion. 2000;40:1308–1312
  106. Wagner SJ, Maroff G, Katz AJ, et al. Comparison of bacterial growth in single and pooled platelet concentrations after deliberate inoculation and storage. Transfusion. 1995;35:298–303
  107. Heal JM, Jones ME, Forey J, et al. Fatal Salmonella septicemia after platelet transfusion. Transfusion. 1987;27:2–5
  108. Kleinman S, Dumont LJ, Tomasulo P, et al. The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: An illustration of the need for proper risk assessments. Transfusion. 2009;49:903–912
  109. Hogman CF, Engstrand L. Factors affecting growth of Yersinia enterocolitica in cellular blood platelets. Transfus Med Rev. 1996;10:259–275
  110. Murphy WG, Foley M, Doherty C, et al. Screening platelet concentrates for bacterial contamination: Low numbers of bacteria and slow growth in contaminated units mandate an alternate approach to product safety. Vox Sang. 2008;95:13–19
  111. Benjamin RJ, Wagner SJ. The residual risk of sepsis: Modeling the effect of concentration on bacterial detection in two-bottle culture systems and an estimation of false-negative culture rates. Transfusion. 2007;47:1381–1389
  112. Eder AF, Kennedy JM, Dy BA, et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: The American Red Cross experience (2004-2006). Transfusion. 2007;47:1134–1142
  113. Ramirez-Arcos S, Chin-Yee I, Hume H, et al. Fatal septic shock associated with transfusion-transmitted Serratia marcescens. Transfusion. 2006;46:679–681
  114. Ramirez-Arcos S, Jenkins C, Dion J, et al. Canadian experience with detection of bacterial contamination in apheresis platelets. Transfusion. 2007;47:421–429
  115. de Korte D, Curvers K, de Kort WL, et al. Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands. Transfusion. 2006;46:476–485
  116. Schmidt M. Comparison of different methods of bacterial detection in blood components. ISBT Sci Ser. 2009;4:80–86
  117. Eder AF, Kennedy JM, Dy BA, et al. Limiting and detecting bacterial contamination of apheresis platelets: Inlet-line diversion and increased culture volume improve component safety. Transfusion. 2009;49:1554–1563
  118. Fuller AK, Uglik KM, Savage WM, et al. Bacterial culture reduces but does not eliminate the risk of septic transfusion reactions to single-donor platelets. Transfusion. 2009;49:2588–2593
  119. Yomtovian RA, Palavecino EL, Dysktra AH, et al. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion. 2006;46:719–730
  120. Kleinman SH, Kamel HT, Harpool DR, et al. Two-year experience with aerobic culturing of apheresis and whole-blood-derived platelets. Transfusion. 2006;46:1787–1794
  121. Benjamin RJ, Kline L, Dy BA, et al. Bacterial contamination of whole-blood-derived platelets: The introduction of sample diversion and prestorage pooling with culture testing in the American Red Cross. Transfusion. 2008;48:2348–2355
  122. Larsen CP, Ezligini F, Hermansen NO, et al. Six years' experience of using the Bact/ALERT system to screen all platelet concentrates to estimate the frequency of false-negative results. Vox Sang. 2005;88:93–97
  123. Schrezenmeier H, Walther-Weuke G, Mullter TH, et al. Bacterial contamination of platelet concentrates: Results of a prospective multicenter study comparing pooled whole-blood-derived platelets and apheresis platelets. Transfusion. 2007;47:644–652
  124. Mohr H, Bayer A, Gravemann U, et al. Elimination and multiplication of bacteria during preparation and storage of buffy-coat-derived platelet concentrates. Transfusion. 2006;46:949–955
  125. Webert MA, Blajchman MA. Transfusion-related acute lung injury. Curr Opin Hematol. 2005;12:480–487
  126. Kopko PM, Paglieroni TG, Popovsky MA, et al. TRALI: Correlation of antigen-antibody and monocyte activation in donor-recipient pairs. Transfusion. 2003;43:177–184
  127. Eder AF, Herron R, Strupp A, et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion. 2007;47:599–607
  128. Eastlund T, McGrath PC, Burkart P. Platelet transfusion reaction associated with inter-donor HLA incompatibility. Vox Sang. 1988;55:157–160
  129. Bux J, Hoch J, Bindl L, et al. Transfusion-associated acute pulmonary insufficiency. Diagnostic confirmation by the demonstration of granulocytic antibodies. J Dtsch Med Wochenschr. 1994;119:19–24(in German)
  130. Ramanthan RK, Triulzi DJ, Logan TF. Transfusion-related acute lung injury following random-donor platelet transfusion: A report of two cases. Vox Sang. 1997;73:43–45
  131. Lin Y, Kanani N, Naughton F, et al. Case report: Transfusion-related acute lung injury (TRALI)—A clear and present danger. Can J Anaesth. 2007;J4:1011–1016
  132. Salman SS, Fernandez Perez ER, Stubbs JR, et al. The practice of platelet transfusion in the intensive care unit. J Intensive Care Med. 2007;22:105–110
  133. Win N, Chapman CE, Bowles KM, et al. How much residual plasma may cause TRALI?. Transfus Med. 2008;18:276–280
  134. Silliman CC, Curtis BR, Kopko PM, et al. Donor antibodies to HNA-3a implicated in TRALI reactions prime neutrophils and cause PMN-mediated damage to human pulmonary microvascular endothelial cells in a two-event in vivo model. Blood. 2007;109:1752–1755
  135. ISBT Working Party on Granulocyte Immunobiology: Recommendations of the ISBT Working Party on Granulocyte Immunobiology for leukocyte antibody screening in the investigation and prevention of antibody-mediated transfusion-related acute lung injury. Vox Sang. 2008;96:266–269
  136. Reil A, Keller-Stanislawski B, Gunay S, et al. Specificities of leukocyte alloantibodies in transfusion-related acute lung injury and results of leukocyte antibody screening of blood donors. Vox Sang. 2008;95:313–317
  137. Davoren A, Curtis RJ, Shulman IA, et al. TRALI due to granulocyte-agglutinating human nuetrophil antigen-3a(5b) alloantibodies in donor plasma: A report of 2 fatalities. Transfusion. 2003;43:641–645
  138. Fadeyi EA, Adams S, Sheldon S, et al. A preliminary comparison of the prevalence of transfusion reactions in recipients of platelet components from donors with and without human leukocyte antigen antibodies. Vox Sang. 2008;94:324–328
  139. Triulzi D. Transfusion-related acute lung injury: Current concepts for the clinician. Anesth Analg. 2009;108:770–776
  140. Seeger W, Schneider U, Kreusler B, et al. Reproduction of transfusion-related acute lung injury in an ex-vivo lung model. Blood. 1990;76:1438–1444
  141. Chapman CE, Stainsby D, Jones D, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of the preferential use of male donor plasma. Transfusion. 2009;49:440–452
  142. Palfi M, Berg S, Berlin G. A randomized controlled trial of transfusion-related acute lung injury: Is plasma from multiparous blood donors dangerous?. Transfusion. 2001;41:317–322
  143. Wright SE, Snowden CP, Athey SC, et al. Acute lung injury after abdominal aortic aneurysm repair: The effect of excluding donations from females from the production of fresh-frozen plasma. Crit Care Med. 2008;36:1796–1802
  144. Nakazawa H, Ohnishi H, Okazaki H, et al. Impact of fresh-frozen plasma from male-only donors versus mixed-sex donors on postoperative respiratory function in surgical patients: A prospective case-control study. Transfusion. 2009;49:2434–2441
  145. Wendel S, Biagini S, Trigo F, et al. Measures to prevent TRALI. Vox Sang. 2007;92:258–277
  146. Hume HA. TRALI: Moving toward prevention. Transfusion. 2009;49:402–405
  147. Murphy MF, Navarette C, Massey E. Donor screening as a TRALI reduction strategy. Transfusion. 2009;49:1779–1782
  148. van Stein D, Beckers EA, Sintnicolaas K, et al. Transfusion-related acute lung injury in the Netherlands: An observational study. Transfusion. 2010;50:213–220
  149. Kopko P, Silva M, Shulman I, et al. AABB survey of transfusion-related acute lung injury policies and practices in the United States. Transfusion. 2007;47:1679–1685
  150. Watkins TR, Rubenfeld GD, Martin TR, et al. Effects of leukoreduced blood on acute lung injury after trauma: A randomized controlled trial. Crit Care Med. 2008;36:1493–1499
  151. Silliman CC. The transfusion of pre-storage leukoreduced packed red blood cells to injured patients. Crit Care Med. 2008;36:1661–1662
  152. Watkins TR, Nathens AB. TRALI: A new case definition, a new epidemic?. Am J Respir Crit Care Med. 2007;176:839–842
  153. Davis A, Mandal R, Johnson M, et al. A touch of TRALI. Transfusion. 2008;48:541–545
  154. Silliman C. High volume transfusion from male-only versus female donor plasma and hypoxemia in the critically ill. Crit Care Med. 2007;35:1775
  155. Welsby IJ, Troughton M, Phillips-Bute B, et al. The relationship of plasma transfusion from female and male donors with outcome after cardiac surgery. J Thorac Cardiovasc Surg. 2010 Feb 22;(Epub ahead of print)
  156. Middleburg RA, van Stein D, Zupanska B, et al. Inconsistent association between donor gender and clinically-defined TRALI. Vox Sang. 2008;95(Suppl. 1):165;(abstract)
  157. Gong MN, Thompson BT, Williams P, et al. Clinical predictors of and mortality in acute respiratory distress syndrome: Potential role of red-cell transfusion. Crit Care Med. 2005;33:1191–1198
  158. Tormey C, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion. 2009;49:505–512
  159. Pineda AA, Taswell HF, Brzica SJ. Delayed hemolytic transfusion reaction: An immunologic hazard of blood transfusion. Transfusion. 1978;18:1–7
  160. Linden JV, Wagner K, Voytovich AE, et al. Transfusion errors in New York State. Transfusion. 2000;40:1207–1213
  161. Callum JL, Kaplan HS, Merkley LL, et al. Reporting of near-miss events for transfusion medicine: Improving transfusion safety. Transfusion. 2001;41:1204–1211
  162. Mercuriliali F, Ineilleri F, Colotti MT, et al. One-year use of the Bloodloc system in an orthopedic institute. Transfus Clin Biol. 1994;1:227–230
  163. Figueroa P, Zinan A, Wheeler C, et al. Nearly two decades using the check-type to prevent ABO-incompatible transfusions: One institution's experience. Am J Clin Pathol. 2006;126:1–5
  164. Lau FY, Wong R, Chui CH, et al. Improvement in transfusion safety using a specially-designed transfusion wristband. Transfus Med. 2000;10:121–124
  165. Sandler S, Langberg A, Dotinalek L. Bar code technology improves positive patient identification and transfusion safety. Dev Biol. 2005;120:19–24
  166. Turner CL, Casbard AC, Murphy MF. Barcode technology: Its role in increasing the safety of blood transfusion. Transfusion. 2003;43:1200–1209
  167. Wenz B, Burns ER. Improvement in transfusion safety using a new blood-unit and patient identification system as part of safe transfusion practice. Transfusion. 1991;31:401–403
  168. Ahrens N, Pruss A, Kiesewetter H, et al. Failure of bedside ABO testing is still the most common cause of incorrect blood transfusion in the barcode era. Transfus Apheresis Sci. 2005;33:25–29
  169. Goodnough LT, Viele M, Fontaine MJ, et al. Implementation of a two-specimen requirement for verification of ABO/Rh for blood transfusion. Transfusion. 2009;49:1321–1328
  170. 69 Federal Register 9120, February 26, 2004. See 21 CFR 606. 121c (13)
  171. Higgins JM, Sloan SR. Stochastic modeling of human RBC alloimmunization: Evidence for a distinct population of immunologic responders. Blood. 2008;112:2546–2553
  172. Schonewille H, van de Watering LM, Loomans DS, et al. Red blood cell alloantibodies after transfusion: Factors influencing incidence and specificity. Transfusion. 2006;46:250–256
  173. Schonewille H, van de Watering LMG, Brand A. Additional red blood cell alloantibodies after blood transfusion in a nonhematologic alloimmunized cohort: Is it time to take precautionary measures?. Transfusion. 2006;46:630–635
  174. Schonewille H, de Vries RPR, Brand A. Alloimmune response after additional red-blood-cell antigen challenge in immunized hemato-oncology patients. Transfusion. 2009;49:453–457
  175. Pomper G, Simpson M. The prevention of alloimmunization: A balance of precaution, expectation, and outcome. Transfusion. 2009;49:406–408
  176. Young P, Uzieblo A, Trulock E, et al. Autoantibody formation after alloimmunization: Are blood transfusions a risk for autoimmune hemolytic anemia?. Transfusion. 2004;44:67–72
  177. Heddle N, Soutar R, O'Hoski P, et al. A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol. 1995;91:1000–1005
  178. Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood. 2000;96:3369–3373
  179. Osby M, Shulman I. Phenotype matching of donor red blood cell units for non-alloimmunized sickle-cell disease patients: A survey of 1182 North-American laboratories. Arch Pathol Lab Med. 2005;129:190–193
  180. Cox J, Steane E, Cunningham G, et al. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle-cell disease. Arch Intern Med. 1988;148:2485–2489
  181. Castro O, Sandler SG, Houston-Yu P, et al. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle-cell disease: Theoretical and practical implications. Transfusion. 2002;42:684–690
  182. Afenyi-Annan A, Brecher ME. Transfusion phenotype matching for sickle-cell disease patients. Transfusion. 2004;44:619–620
  183. Luban NL. Variability in rates of alloimmunization in different groups of children with sickle-cell disease: Effect of ethnic background. Am J Pediatr Hematol Oncol. 1989;11:314–319
  184. Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle-cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322:1617–1621
  185. Beiboer SH, Wieringa-Jelsma T, Maaskant-van Wijk PA, et al. Rapid genotyping of blood cohort antigens by multiplex polymerase chain reaction and DNA microarray hybridization. Transfusion. 2005;45:667–679
  186. Bugert P, McBride S, Smith G, et al. Microarray-based genotyping for blood cohorts: Comparison of gene array and 5′-nuclease assay techniques with human platelet antigen as a model. Transfusion. 2005;45:654–659
  187. Denomme GA, Van Oene M. High-throughput multiplex single-nucleotide polymorphism analysis for red cell and platelet antigen genotypes. Transfusion. 2005;45:660–666
  188. Hashmi G, Shariff T, Seul M, et al. A flexible array format for large-scale, rapid blood cohort DNA typing. Transfusion. 2005;45:680–688
  189. Hashmi G, Shariff T, Zhang Y, et al. Determination of 24 minor red blood cell antigens for more than 2,000 blood donors by high throughput DNA analysis. Transfusion. 2007;47:736–747
  190. Klapper E, Zhang Y, Figueroa P, et al. Toward extended phenotype compatibility: A new operational paradigm for the transfusion service. Transfusion. 2009 Nov 19;(Epub ahead of print)
  191. Williamson LM, Stainsby D, Jones H, et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of post-transfusion purpura and transfusion-associated graft-versus-host disease. Transfusion. 2007;47:1455–1467
  192. Yasuura K, Okamoto H, Matsuura A. Transfusion-associated graft-versus-host disease with transfusion practice in cardiac surgery. J Cardiovasc Surg. 2000;41:377–380
  193. Rososhansky S, Badonnel MC, Hiestand LL, et al. Transfusion-associated graft-versus-host disease in an immunocompetent patient following cardiac surgery. Vox Sang. 1999;76:59–63
  194. Luban NL, DePalma L. Transfusion-associated graft-versus-host disease in the neonate: Expanding the spectrum of disease. Transfusion. 1996;36:101–103
  195. Anderson KC. Current trends: Evolving concepts in transfusion medicine. Leukodepleted cellular blood components for prevention of transfusion-associated graft-versus-host disease. Transfus Sci. 1995;16:265–268
  196. Andrzejewski C, Popovsky MA. Transfusion-associated adverse pulmonary sequelae: Widening our perspective. Transfusion. 2005;45:1048–1050
  197. Rana R, Fernandez-Perez E, Khan SA, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: A retrospective study. Transfusion. 2006;46:1478–1483
  198. Pineda AA, Taswell HF. Transfusion reactions associated with anti-IgA antibodies: Report of four cases and review of the literature. Transfusion. 1975;15:10–15
  199. McFarland JG. Post-transfusion purpura. In:  Popovsky MA editors. ed 3. Transfusion reactions. Bethesda, MD: AABB Press; 2007;p. 275–299
  200. Goodnough LT, Verbrugge D, Vizmeg K, et al. Identifying elective orthopedic surgical patients transfused with amounts of blood in excess of need: The transfusion trigger revisited. Transfusion. 1992;32:648–653
  201. Kim DM, Brecher ME, Estes TJ, et al. Relationship of hemoglobin level and duration of hospitalization after total hip arthroplasty: Implications for the transfusion target. Mayo Clin Proc. 1993;68:37–41
  202. Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001;345:1230–1236
  203. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555–1562
  204. Silliman CC, Clay KL, Thurman GW, et al. Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase. J Lab Clin Med. 1994;124:684–694
  205. Zallen G, Moore EE, Ciesla DJ, et al. Stored red blood cells selectively activate human neutrophils to release IL-8 and secretory PLA2. Shock. 2000;13:29–33
  206. Chin-Yee I, Keeney M, Krueger L, et al. Supernatant from stored red cells activates neutrophils. Transfus Med. 1998;8:49–56
  207. Fransen E, Maessen J, Denterner M, et al. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest. 1999;116:1233–1239
  208. Zallen G, Offner PJ, Moore EE, et al. Age of transfused blood is an independent risk factor for post-injury multiple-organ failure. Am J Surg. 1999;178:540–572
  209. Johnson JL, Moore EE, Offner PJ, et al. Resuscitation with a blood substitute abrogates pathologic post-injury neutrophil cytotoxic function. J Trauma. 2001;50:449–455
  210. Hachida M, Hanayama N, Okamura T, et al. The role of leukocyte depletion in reducing injury to myocardium and lung during cardiopulmonary bypass. ASAIO J. 1995;41:M291–294
  211. Gu YJ, de Vries AJ, Boonstra PW, et al. Leukocyte depletion results in improved lung function and reduced inflammatory response after cardiac surgery. J Thorac Cardiovasc Surg. 1996;112:494–500
  212. Pearl JM, Drinkwater DC, Laks H, et al. Leukocyte-depleted reperfusion of transplanted human hearts prevents ultrastructural evidence of reperfusion injury. J Surg Res. 1992;52:298–308
  213. Habib RH, Zacharias A, Engoren M. Determinants of prolonged mechanical ventilation after coronary artery bypass grafting. Ann Thorac Surg. 1996;62:1164–1171
  214. Vamvakas EC, Carven JH. Allogeneic blood transfusion and postoperative duration of mechanical ventilation: Effects of red cell supernatant, platelet supernatant, plasma components, and total transfused fluid. Vox Sang. 2002;82:141–149
  215. Maetani S, Nishikawa T, Tobe T, et al. Role of blood transfusion in organ system failure following major abdominal surgery. Ann Surg. 1986;203:275–281
  216. Sauaia A, Moore FA, Moore EE, et al. Early predictors of post-injury multiple-organ failure. Arch Surg. 1994;129:39–45
  217. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288:1499–1507
  218. Vedder NB, Fouty BW, Winn RK, et al. Role of neutrophils in generalized reperfusion injury associated with resuscitation from shock. Surgery. 1989;106:509–516
  219. Anderson BO, Harken AH. Multiple-organ failure: Inflammatory priming and activation sequences promote autologous tissue injury. J Trauma. 1990;30:S44–S49
  220. Botha AJ, Moore FA, Moore EE, et al. Post-injury neutrophil priming and activation states: Therapeutic challenges. Shock. 1995;3:157–166
  221. Hébert PC, Blajchman MA, Cook DJ, et al. Do blood transfusions improve outcomes related to mechanical ventilation?. Chest. 2001;119:1850–1857
  222. Forceville X, Plouvier E, Chaise C. The deleterious effect of heminic iron in transfused intensive-care-unit patients. Crit Care Med. 2002;30:1182–1183
  223. Zimmerman JJ. Defining the role of oxyradicals in the pathogenesis of sepsis. Crit Care Med. 1995;23:616–617
  224. Alayash AI, Ryan BA, Cashon RE. Peroxynitrite-mediated heme oxidation and protein modification of native and chemically modified hemoglobins. Arch Biochem Biophys. 1998;349:65–73
  225. McCord JM. Iron, free radicals, and oxidative injury. Semin Hematol. 1998;35:5–12
  226. Shander A, Cappelini MD, Goodnough LT. Iron overload and toxicity: The hidden risk of multiple transfusions. Vox Sang. 2009;97:185–197
  227. Hébert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA. 2003;289:1941–1949
  228. Fergusson D, Hébert PC, Lee SK, et al. Clinical outcomes following institution of universal leukoreduction of blood transfusions for premature infants. JAMA. 2003;289:1950–1956
  229. Vamvakas EC. White-blood-cell-containing allogeneic blood transfusion, postoperative infection, and mortality: A meta-analysis of observational, “before-and-after” studies. Vox Sang. 2004;86:111–119
  230. Jensen LS, Kissmeyer-Nielsen P, Wolff B, et al. Randomized comparison of leukocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet. 1996;348:841–845
  231. Nielsen HJ, Hammer JH, Kraup AL, et al. Pre-storage leukocyte filtration may reduce leukocyte-derived bioactive substance accumulation in patients operated for burn trauma. Burns. 1999;25:162–170
  232. Titlestad IL, Ebbesen LS, Ainsworth AP, et al. Leukocyte-depletion of blood components does not significantly reduce the risk of infectious complications: Results of a double-blind, randomized study. Int J Colorectal Dis. 2001;16:147–153
  233. Dzik WH, Anderson JK, O'Neill EM, et al. A prospective, randomized clinical trial of universal WBC reduction. Transfusion. 2002;42:1114–1122
  234. Wallis JP, Chapman CE, Orr KE, et al. Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery. Transfusion. 2002;42:1127–1134
  235. van Hilten JA, van de Watering LMG, van Bockel JH, et al. Effects of transfusion with red cells filtered to remove leukocytes: Randomized controlled trial in patients undergoing major surgery. BMJ. 2004;328:1281–1284
  236. Bracey AW, Radovancevick R, Nussimeier NA, et al. Leukocyte-reduced blood in open-heart surgery patients: Effects on outcome. Transfusion. 2002;42(Suppl):5S
  237. Nathens AB, Nester TA, Rubenfeld GD, et al. The effects of leukoreduced blood transfusion on infection risk following injury: A randomized controlled trial. Shock. 2006;26:342–347
  238. Vamvakas EC. White-blood-cell-containing allogeneic blood transfusion and postoperative infection or mortality: An updated meta-analysis. Vox Sang. 2007;92:224–232
  239. Bilgin YM, Brand A. Transfusion-related immunomodulation: A second hit in an inflammatory cascade?. Vox Sang. 2008;95:261–271
  240. Vamvakas E, Blajchman MA. Transfusion-related immunomodulation (TRIM): An update. Blood Rev. 2007;21:327–348
  241. Dzik WH. Blood components to achieve hemostasis for surgery and invasive procedures. In:  Simon TL,  Snyder EL,  Solheim BG,  Stowell CP,  Strauss RG,  Petrides M editor. ed 4. Rossi's Principles of transfusion medicine. Oxford, UK: Wiley-Blackwell; 2009;p. 575–588
  242. Spiess B. Red cell transfusions and guidelines: A work in progress. Hem Clin North Am. 2007;21:185–200
  243. Surgenor SD, Hampers MJ, Corwin HL. Is blood transfusion good for the heart?. Crit Care Med. 2001;29:442–444
  244. Fernandes CJ, Akamine N, De Marco FVC, et al. Red blood cell transfusion does not increase oxygen consumption in critically ill septic patients. Crit Care. 2001;5:362–367
  245. den Uil CA, Klijn E, Lagrand WK, et al. The microcirculation in health and critical disease. Prog Cardiovasc Dis. 2008;51:161–170
  246. Stiner ME, Stowell C. Does red-blood-cell storage affect clinical outcome? When in doubt, do the experiment. Transfusion. 2009;49:1286–1290
  247. National Institutes of Health . In: National Heart Lung and Blood Institute: State-of-the Science Symposium in Transfusion Medicine and Hemostasis/Thrombosis. Bethesda, MD: Lister Hill Auditorium, September 14 and 15. 2009;
  248. Deans KJ, Minneci PC, Suffredini AF, et al. Randomization in clinical trials of titrated therapies: Unintended consequences of using fixed treatment protocols. Crit Care Med. 2007;35:1509–1516
  249. Deans KJ, Minneci PC, Danner RL, Eichacker PQ, Nathanson C. Practice misalignments in randomized controlled trials: identification, impact, and potential solutions. Anesth Analg. 2009 Oct 9;(Epub ahead of print)
  250. Carson JL, Terrin ML, Maganizer J, et al. Transfusion trigger trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS). Transfusion. 2006;46:2192–2206
  251. Carson JL, Terrin ML, Barton FB, et al. A pilot randomized trial comparing symptomatic versus hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion. 1998;38:522–529
  252. Hébert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically-ill patients with cardiovascular diseases?. Crit Care Med. 2001;29:227–234
  253. Baxter BT, Minion DJ, McCance CL, et al. Rational approach to postoperative transfusion in high-risk patients. Am J Surg. 1993;166:720–725
  254. Kirpalani H, Whyte RK, Andersen C, et al. The Premature Infants in Need of Transfusion (PINT) study: A randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low-birth-weight infants. J Pediatr. 2006;149:301–307
  255. Whyte RK, Kirpalani H, Asztalos EV, et al. Neurodevelopmental outcome of extremely low-birth-weight infants randomly assigned to restrictive or liberal hemoglobin thresholds for blood transfusion. Pediatrics. 2009;123:207–213
  256. Bell EF, Strauss RG, Widness JA, et al. Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants. Pediatrics. 2005;115:1685–1691
  257. Slichter SJ, Kaufman RM, Assman SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362:600–613
  258. Blajchman MA, Slichter SJ, Heddle NM, et al. New strategies for optimal use of platelet transfusions. In: Hematology Am Soc Hematol Educ Program. 2008;p. 198–204
  259. Heddle NM, Cook RJ, Timmouth A, et al. A randomized controlled trial comparing standard and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood. 2009;113:1564–1573
  260. Platelet transfusion therapy . National Institutes of Health Consensus Conference. Transfus Med Rev. 1987;1:195–200
  261. College of American Pathologists . Practice parameter for the use of fresh frozen plasma, cryoprecipitate, and platelets. JAMA. 1994;271:777–781
  262. Canadian Medical Association Expert Working Group . Guidelines for red blood cell and plasma transfusion for adults and children. Can Med Assoc J. 1997;156(Suppl 11):S1–S29
  263. Norfolk DR, Ancliffe PJ, Contreras M, et al. Consensus conference on platelet transfusion. Royal College of Physicians of Edinburgh, 27-28 November 1997. Br J Haematol. 1998;101:609–617
  264. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1519–1538
  265. British Committee for Standards in Hematology: Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122:10–23
  266. British Committee for Standards in Haematology, Blood Transfusion Task Force , O'Shaughnessy DF, Attenbury C, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate, and cryosupernatant. Br J Haematol. 2004;126:11–28
  267. British Committee for Standards in Haematology: Writing GroupStainsby D, MacLeman S, Thomas D, et al. Guidelines on the management of massive blood loss. Br J Haematol. 2006;135:634–641
  268. Malloy PC, Grassi CJ, Kundu S, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2009;20:S240–S249
  269. Arnold DM, Heddle NM, Kulczycky M, et al. In-vivo recovery and survival of apheresis and whole-blood-derived platelets: A paired comparison in healthy volunteers. Transfusion. 2006;46:257–264
  270. Heddle NM, Arnold DM, Boye D, et al. Comparing the efficacy and safety of apheresis and whole-blood-derived platelet transfusions: A systematic review. Transfusion. 2008;48:1447–1458
  271. Gurkan E, Patah PA, Saliba RM, et al. Efficacy of prophylactic transfusions using single-donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem-cell transplantation. Bone Marrow Transplant. 2007;40:461–464
  272. Fluit CR, Kunst DA, Drenthe-Schonk AM. Incidence of red-cell antibodies after multiple transfusion. Transfusion. 1990;30:532–535
  273. Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion. 1999;39:763–771
  274. Shaz BH, Zimring JC, Demmons DG, et al. Blood donation and blood transfusion: Special considerations for African Americans. Transfus Med Rev. 2008;22:202–214
  275. Hillman NM. Fatal delayed hemolytic transfusion reaction due to anti-c+E. Transfusion. 1979;19:548–551
  276. Heuft HG, Mende W, Blasczyk R. A general change of the platelet transfusion policy from apheresis platelet concentrates to pooled platelet concentrates is associated with a sharp increase in donor exposures and infection rates. Transfus Med Hemother. 2008;35:106–113
  277. Vamvakas EC. Why are all men who have had sex with men even once since 1977 indefinitely deferred from donating blood?. Transfusion. 2009;49:1037–1042
  278. Kopko PM, Marshall CS, Mackenzie MR, et al. Transfusion-related acute lung injury: Report of a look-back investigation. JAMA. 2002;287:1968–1971
  279. Vamvakas EC, Blajchman MA. Universal WBC reduction: The case for and against. Transfusion. 2001;41:691–712
  280. Allain JP, Bianco C, Blajchman MA, et al. Protecting the blood supply from emerging pathogens: The role of pathogen inactivation. Transfus Med Rev. 2005;19:110–126
  281. McCullough J. Pathogen inactivation: A new paradigm for blood safety. Transfusion. 2007;47:2180–2184
  282. Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: Making decisions about new technologies. Report of a consensus conference. Transfusion. 2007;47:2338–2347
  283. Osselaer JC, Messe N, Hervig T, et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion. 2008;48:1061–1071
  284. Osselaer JC, Cazenave JP, Lambermont M, et al. An active hemovigilance program characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang. 2008;94:315–323
  285. Politis C, Kavalierou L, Hantziara S, et al. Quality and safety of fresh frozen plasma inactivated and leukoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. Vox Sang. 2007;92:319–326
  286. Larrea L, Calaburg M, Solves MA, et al. Our nine years' experience in plasma inactivation. Vox Sang. 2007;93(Suppl. 1):167
  287. Reddy HL, Dayan AD, Cavagnaro J, et al. Toxicity-testing of a novel riboflavin-based technology for pathogen reduction and white-blood-cell inactivation. Transfus Med Rev. 2008;22:133–153
  288. Prowse C. Properties of pathogen-inactivated plasma components. Transfus Med Rev. 2009;23:124–133
  289. Custer B, Hochs JS. Cost-effectiveness analysis: What it really means for transfusion-medicine decision making. Transfus Med Rev. 2009;23:1–12
  290. Osselaer JC, Doyen C, Defoin L, et al. Universal adoption of pathogen inactivation of platelet components: Impact on platelet and red-blood-cell component use. Transfusion. 2009;49:1412–1422
  291. Cazenave JP, Waller C, Mendel I, et al. Clinical experience with conventional versus INTERCEPT platelet concentrates transfused to all patients during two one-year periods: Reduction of adverse events with equivalent use of blood products. Vox Sang. 2008;95(Suppl. 1):305–306
  292. Goodrich R, Follea G, Roberts T. Clinical evaluation of Mirasol PRT-treated apheresis platelets in thrombocytopenic patients. Transfusion. 2008;48(Suppl. 2):20;(abstract)
  293. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial. Blood. 2004;104:1534–1541
  294. Solheim BG. Pathogen reduction of blood components. Transfus Apheresis Sci. 2008;39:75–82
  295. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: An overview. Transfus Apheresis Sci. 2006;35:83–90
  296. Flesland O. A comparison of complication rates based on published hemovigilance data. Intensive Care Med. 2007;33(Suppl 1):S17–S21
  297. Renaudier P, Schlanger S, Mai MPV, et al. Epidemiology of transfusion-related acute lung injury in France: Preliminary results. Transfus Med Hemother. 2009;35:89–91
  298. MacLennan S, Barbara JA. Risks and side-effects of therapy with plasma and plasma factions. Best Pract Res Clin Haematol. 2006;19:169–189
  299. Coignard BP, Colquhoun SD, Nguyen GT, et al. Intraoperative deaths in liver transplant recipients associated with the use of solvent/detergent plasma. Hepatology. 2002;36:A209;(abstract)
  300. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, et al. Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe?. Transfus Med. 2006;16:266–275
  301. Leiss W, Tyshenko M, Krewski D. Men-having-sex-with-men donor-deferral risk assessment: An analysis using risk management principles. Transfus Med Rev. 2008;22:35–57

PII: S0887-7963(09)00119-9

doi: 10.1016/j.tmrv.2009.11.001

Transfusion Medicine Reviews
Volume 24, Issue 2 , Pages 77-124 , April 2010

Article Tools

* Image Usage & Resolution